A subset of NSCLC-carrying specific genetic mutations of epidermal growth factor receptor (EGFR) can be effectively treated by EGFR tyrosine kinase inhibitor (TKI)-mediated targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.